Diphenylcyclopropenone alleviates trachyonychia in alopecia universalis [PDF]
International Journal of DermatologyAhu Yorulmaz
semanticscholar +4 more sources
Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report [PDF]
International Journal of Rheumatic DiseasesOcrelizumab is a humanized monoclonal antibody, which acts as an anti‐CD20 antibody. It is used as a treatment of both relapsing–remitting multiple sclerosis (RRMS) and Progressive types. The aim of this study is to report the first patient with alopecia
Mahshid Mahyad +3 more
openalex +2 more sources
JEADV Clinical Practice, Volume 4, Issue 5, Page 1182-1185, December 2025.Psoriasis vulgaris and psoriatic arthritis are common diseases that can lead to considerable impairment of quality of life. The coexistence of alopecia universalis and psoriasis may suppose a therapeutic challenge.
J. Wagner +4 more
semanticscholar +2 more sources
ALOPECIA UNIVERSALIS IN ULCERATIVE COLITIS
International Journal of Advanced ResearchIntroduction-Inflammatory bowel disease (IBD) comprises of predominantly ulcerative colitis followed by Crohns disease in India. They affect predominantly gastro-intestinal area but extra-intestinal involvement also occurs which include skin also, symptoms of which can start before, simultaneously or later in the course of IBD.
Parveen Malhotra +5 more
openaire +2 more sources
Treatment of alopecia totalis/universalis/focalis with vitamin D and analogs: Three case reports and a literature review [PDF]
, 2021 BACKGROUND: Alopecia areata (AA) is an inflammatory disease with autoimmune, environmental, and inherited components directed at the hair follicle, either limited to patchy hair loss over the scalp (Focalis, AF), total loss of scalp hair (Totalis, AT ...
Alexopoulos, Alexios +4 more
core +3 more sources
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis [PDF]
Journal of dermatology (Print)This post-hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis (AT) and alopecia universalis (AU).
Banerjee, Anindita +16 more
core +2 more sources
Successful Therapy of Alopecia Universalis Using a Combination of Systemic Methotrexate and Corticosteroids and Topical 5% Minoxidil. [PDF]
Clin Cosmet Investig Dermatol, 2022 Ruchiatan K +5 more
europepmc +5 more sources
Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients. [PDF]
Int J Environ Res Public Health, 2021 Alopecia Universalis (AU) is the most severe form of Alopecia Areata and is caused by cytotoxic T-cells reacting with follicular autoantigens, producing complete loss of scalp and body hair. Alemtuzumab is a highly efficacious monoclonal antibody used in
Borriello G, Ianniello A, Toosy AT.
europepmc +3 more sources
Alopecia universalis after injection of messenger RNA COVID-19 vaccine. A case report. [PDF]
IDCases, 2023 Iwata K, Kunisada M.
europepmc +2 more sources